Novel mobility test to assess functional vision in patients with inherited retinal dystrophies-Reference-Cited by-同舟云学术

Novel mobility test to assess functional vision in patients with inherited retinal dystrophies

Published:2017-08-31 Issue:3 Volume:46 Page:247-259
ISSN:1442-6404
Container-title:Clinical & Experimental Ophthalmology
language:en
Short-container-title:Clinical & Experimental Ophthalmology

Author:

Chung Daniel C¹^ORCID,McCague Sarah²,Yu Zi-Fan³,Thill Satha³,DiStefano-Pappas Julie⁴,Bennett Jean²⁵^ORCID,Cross Dominique²,Marshall Kathleen²,Wellman Jennifer¹,High Katherine A¹

Affiliation:

1. Spark Therapeutics, Inc.; Philadelphia Pennsylvania USA

2. Center for Cellular and Molecular Therapeutics; Children's Hospital of Philadelphia; Philadelphia Pennsylvania USA

3. Statistics Collaborative, Inc.; Washington District of Columbia USA

4. Westat, Inc.; Philadelphia Pennsylvania USA

5. Perelman School of Medicine; University of Pennsylvania; Philadelphia Pennsylvania USA

Funder

Spark Therapeutics, Inc

Publisher

Wiley

Subject

Ophthalmology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ceo.13022/fullpdf

Reference23 articles.

1. Does mobility performance of visually impaired adults improve immediately after orientation and mobility training?;Soong;Optom Vis Sci,2001

2. Orientation and mobility assessment in retinal prosthetic clinical trials;Geruschat;Optom Vis Sci,2012

3. Evaluation of a portable collision warning device for patients with peripheral vision loss in an obstacle course;Pundlik;Invest Ophthalmol Vis Sci,2015

4. Traditional measures of mobility performance and retinitis pigmentosa;Geruschat;Optom Vis Sci,1998

5. Mobility of people with retinitis pigmentosa as a function of vision and psychological variables;Haymes;Optom Vis Sci,1996

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa;American Journal of Ophthalmology;2024-11

2. Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1/2 trial;Nature Communications;2024-09-10

3. Therapies for Inherited Retinal Dystrophies: What is Enough?;Drug Discovery Today;2024-09

4. Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study;The Lancet;2024-09

5. Comment on “PRISMA–COSMIN guidance for reporting systematic reviews of outcome measurement instruments”;Quality of Life Research;2024-07-09